PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES

COMPARATIVE CLINICAL STUDIES OF *ECLIPTA PROSTRATA* WITH MARKETED POLYHERBAL FORMULATION LIVER CARE CHURNA FOR LIVER DISEASE

Jitendra S. Patel^{*1}, Hemangi J. Patel¹, K. N. Patel², A K Seth¹, Keyur D. Patel³

1. Department of Pharmacy, Sumandeep Vidyapeeth, Pipariya, Vadodara, Gujarat.

2. Sal college of Pharmacy, Ahmedabad, Gujarat

3. Vishveshpuram College of Pharmacy, Banglore

ABSTRACT

Comparative study of indigenous plant *Eclipta prostrata* and marketed Polyherbal formulation Liver care Churna were selected for clinical investigation of hepatoprotective activity. Clinical study of patients were suffering from liver disease jaundice, they were selected. The antihepatotoxic activity of the herb Eclipta prostrata and marketed polyherbal formulation studied on human. Marketed Polyherbal formulation was made by preparing mixture of powder of different plants of herb which were known to be rich source of hepatoprotective activity. The ability of whole plant dried drug powder of Eclipta prostrata (traditionally used in treatment of jaundice) and marketed formulation were tested for hepatoprotective activity on 191 patients who were suffering from liver disease. Among them 93 patients for Liver care Churna and 98 patients for Eclipta prostrata were tested. The powder Liver care Churna and Eclipta prostrata was given thrice a day (morning, noon and night, 3gm each time) orally with water for 30-45 days depending on the severity of the disease. The comparative clinical studies was done by selection and screening of patient of different age by administering the drug *Eclipta* prostrata and Liver care Churna. The clinical parameters were evaluated like SGPT, Bilirubin and HB. The whole plant of drug *Eclipta prostrata* and the marketed polyherbal formulation Liver care Churna both produced remarkable reduces in SGPT, Bilirubin while increase in HB.

Key words: Antihepatotoxic activity, *Eclipta prostrata*, Liver care Churna, Clinical study

INTRODUCTION

Liver plays a vital role in the metabolism and elimination of various exogenous and endogenous compounds. As a result of its continuous involvement, it is susceptible to toxic injuries caused by certain agents and any damage to hepatic cells disturb body metabolism. In recent times lot of interest has been generated to find out a natural remedy for hepatic disorders caused by toxins like alcohol and hepatitis virus^[1]. The agent should protect against such damage, especially of one which facilitates regeneration by proliferation of parenchymal cells after damage and arrest growth of fibrous tissue^[2]. There is not remedy for liver diseases which are so prevalent in the population. The treatment is mainly symptomatic^[2].

The powder of whole plant Eclipta prostrata use as hepatoprotective^[3], it improves in hair growth^[4], hepatic tonic^[5], hepatitis^[6], anti diabetes^[7], Antiasthamatic^[8], anti cancer^[9].

Polyherbal formulation name as a Liver care Churna containing *Eclipta prostrata, Embelia officinalis, Terminalia chebula, Phyllanthus amarus, Boerhaavia diffusa, Andrographis paniculata, Terminalia belerica* and *Picrorrhiza kurroa* were made by preparing mixture of different parts of herb which were known to be rich sources of hepatoprotective activity^[10-11]. Clinical trials of marketed Polyherbal formulation shows Antihepatotoxic activity^[12-13].

MATERIAL AND METHOD:

The plant of *Eclipta prostrata* was collected in the month of August 2006 from fields of a village Dugarwada in Modasa Taluka in Sabarkatha (S.K.) District (Gujarat) where it is growing wild. The herb was authenticated by Dr. H.B. Singh, Scientist F & Head, Raw Materials Herbarium & Museum, Council of Scientific and Industrial Research (CSIR), NISCAIR, New Delhi. (Date: o4-08-08, Ref. 1031/62). Marketed formulation Liver care Churna was collected from Rajsha Pharmaceuticals, Ahmedabad, Gujarat.

The ability of whole dried drug Liver care Churna and *Eclipta prostrata* were tested at Sapan Hospital, Bayad, Dist-S.K., Gujarat, for hepatoprotective activity on 191 patients who were suffering from liver disease, their distribution of patients with age and sex shown in Table no.1 & 2. The powder Liver care Churna and *Eclipta prostrata* were given thrice a day (morning, noon and night, 3 gm each time) orally with glucose to the liver damage patients for one, two, three, four and six weeks and treatment was continued until recovered. Comparative pathological parameter like SGPT, Bilirubin and

Haemoglobin were monitored during the treatment. SGPT levels expressed in U/ml, Bilirubin expressed in mg% and Haemoglobin expressed in gm%.

Material and reagents are used in clinical investigations were collected from Span Diagnostic Ltd, Shivam Surgical Ahmedabad. Estimation of SGPT, Bilirubin and HB, parameter was evaluated.

ECLIPTA PROSTRATA				
Age	Patients(98)	M/F	Patients	
		Μ	8	
0-15	12	F	4	
		Μ	18	
16-30	28	F	10	
		М	15	
31-45	31	F	16	
		М	18	
46-60	23	F	5	
		М	4	
61-ABOVE	4	F	0	

Table 1. Distribution of	nationts with Ago and	Son for Folinta nuostuata	
Table 1. Distribution of	patients with Age and	Sex for <i>Eclipta prostrata</i> .	

Table 2: Distribution of patients with Age and Sex for Liver care Churna.

LIVER CARE CHURNA				
Age	Patients(93)	M/F	Patients	
		Μ	1	
0-15	2	F	1	
		Μ	15	
16-30	23	F	8	
		Μ	22	
31-45	37	F	15	
		М	21	
46-60	30	F	9	
		Μ	0	
61-ABOVE	1	F	1	

ESTIMATION OF SGPT^[14-15]

Reagent 1: Buffered alanine α -KG substrate.

Reagent 2: DNPH color reagent.

Reagent 3: sodium hydroxide, 4N.

Reagent 4: Working pyruvate standard, 2mM.

Solution 1: One ml of Reagent No.3 was diluted to 10 ml with distilled water. Reagent 1, 2 & 4 are ready for use as such.

Reagent 1 (Buffered alanine α -KG substrate) 0.5 ml taken in test tube. It was incubated for 37°C for 5 min. fasted serum 0.1 ml was added to the test tube. It was mixed well and incubated for 37°C for 30 min. Reagent 2: DNPH color reagent 0.5 ml was added to the above test tube. It was allow to stand at room temperature for 20 min. Solution 1, 5 ml was added to the solution of the test tube. It was mixed well and allow to stand for 10 min. the absorbance of the solution was measured 505 nm using water as blank.

Estimation of Bilirubin^[16]

The estimation of total and direct Bilirubin is of importance for diagnosis, differentiation and follows up of jaundice. The serum levels of unconjugated Bilirubin rises in the cases of hemolytic jaundice. Whereas conjugated serum Bilirubin levels rises in the cases of obstructive jaundice. Hepatic jaundice is characterized by simultaneous rise in both, conjugated and unconjugated serum Bilirubin levels.

Reagent A: Total Bilirubin reagent.

Reagent B: Direct Bilirubin reagent.

Reagent C: Sodium nitrite reagent.

Reagent D: Artificial standard C = 10mg% Bilirubin.

All reagents in the kit are ready to use as such.

For total Bilirubin estimation 3 ml of reagent A and 0.1 ml of reagent C were mixed by inversion and waited for 30 seconds. Fasted serum 0.15 ml was added. The content was mixed well and incubated for 37°C for 5 min. absorbance was read at 540 nm using water as blank.

For direct Bilirubin estimation 3 ml of reagent B and 0.1 ml of reagent C were mixed by inversion and waited for 30 seconds. Fasted serum 0.15 ml was added. The content was mixed well and incubated for 37°C for 5 min. absorbance was read at 540 nm using water as blank.

The absorbance of the reagent 4 (artificial standard) was read directly against distilled water. The standard once used was discarded. Serum Bilirubin in mg%

Total Billirubin(A) =
$$\frac{Absorbance of T - Absorbance of TB}{Absorbance of Standered} * 10$$

Where T= Total Bilirubin, TB= Total Bilirubin blank, D= Direct Bilirubin, DB= Direct Bilirubin blank.

Determination of Haemoglobin.^[17]

The graduated diluting tube and the micropipette are cleaned thoroughly and dried. The graduated diluting tube is filled with N/10 HCl up to the mark 2 gm or till the micropipette touches the level of acid in the tube. The finger is cleaned with 70% alcohol and it is pricked to obtain a drop of blood. First drop is wiped out. Second drop is sucked in the micropipette up to the mark 20cmm. The blood is immediately deposited at the bottom of the graduated tube. The pipette is rinsed two to three times in HCl. The blood is mixed with the help of stirrer and then solution is allowed to stand for 10-15 minutes so that all Haemoglobin is converted into acid haematin. Then mixture is diluted with distilled water. Distilled water is added drop by drop and every time it is stirred till the exact match with standard glass tubes is obtain and the scale is read on the side of tube.

Statistical analysis

Result of biochemical estimation SGPT, Bilirubin and Haemoglobin were reported by Mean, S.D, SEM and Median. For determination of significant P value inter group difference of each parameter was analyzed separately. One way analysis of variance P value was carried out by Graph Pad statistics software.

RESULTS AND DISCUSSION

The mean values of SGPT for *Eclipta prostrata* initially 987.77, first 654.63, second week 378.69, third week 222.48, fourth week 152.82 and sixth week 62.30 respectively. The P value is < 0.0001, which is considered as highly significant shown in Table 3. The mean values of SGPT for Liver care Churna initially 1092.344, first week 651.0753, second week 446.28, third week 334.8936, fourth week 194.5161 and sixth

week 68 respectively. The P value is < 0.0001, which is considered as highly significant shown in Table 4. Comparative study of SGPT of *Eclipta prostrata* and Liver care Churna is shown in figure 1.

Duration in week	Mean	Standard Deviation	Standard Error of Mean	Median
Initial	947.83	869.90	84.894	621.00
First	635.27	648.86	64.247	390.00
Second	368.88	367.28	38.715	235.00
Third	220.04	227.91	28.489	110.00
Fourth	152.82	145.98	24.675	75.000
Sixth	62.308	16.596	4.436	63.654

 Table No 3: P value of SGPT for Eclipta prostrate

The P value is < 0.0001, considered extremely significant.

Table 4: P value of SGPT for Liver care Churna

Duration in week	Mean	Standard Deviation	Standard Error of	Median
ш жеек		Deviation	Mean	
Initial	1092.3	933.22	96.254	750.00
First	651.08	658.63	67.932	420.00
Second	446.28	463.63	53.182	310.00
Third	334.89	309.64	44.692	210.00
Fourth	194.52	192.65	34.056	90.00
Sixth	68.000	22.935	6.915	75.00

The P value is < 0.0001, considered extremely significant.




Figure 1 Comparative study of SGPT v/s week. Column graph showing value of SGPT for different week using *Eclipta prostrata* and Liver care Churna.

The mean value of Bilirubin for Eclipta prostrata initially 6.336, first week 4.40, second week 3.009, third week 2.174, fourth week 1.678 and sixth week 1.107 respectively. The P value is < 0.0001, which is considered as highly significant shown in Table 5. The mean value of Bilirubin for Liver care Churna initially 5.8516, for first week 3.648, second week 2.737, third week 2.1659, fourth week 1.4516 and sixth week 0.94 respectively. The P value is < 0.0001, which is considered as highly significant shown in Table 6. Comparative study of Bilirubin of *Eclipta prostrata* and Liver care Churna is shown in figure 2.

Duration in week	Mean	Standard Deviation	Standard Error of Mean	Median
Initial	5.595	3.782	0.3745	4.9
First	3.538	2.917	0.2917	2.8
Second	2.667	2.112	0.2326	2.05
Third	2.158	1.354	0.1934	2.1
Fourth	1.443	0.8531	0.1485	1.1
Sixth	0.940	0.1020	0.03075	0.9

 Table 5: P value of Bilirubin for Eclipta prostrata

The P value is < 0.0001, considered extremely significant.

Duration in week	Mean	Standard Deviation	Standard Error of Mean	Median
Initial	5.602	3.758	0.3614	4.85
First	3.698	2.996	0.2938	2.9
Second	2.672	2.105	0.2297	2.0
Third	2.122	1.347	0.1869	2.05
Fourth	1427	0.8450	0.1449	1.075
Sixth	0.9400	0.1020	0.03075	0.9

The P value is < 0.0001, considered extremely significant.




Figure 2

Comparative study of Bilirubin v/s week. Column graph showing value of Bilirubin for different week using *Eclipta prostrata* and Liver care Churna.

The mean Haemoglobin for *Eclipta prostrata* for zero day was considered. As comparison with zero week, Haemoglobin level increase on first, second and third week, on fourth and sixth week haemoglobin level decreases slightly but in comparison with zero week it is increased. The P value is insignificant for haemoglobin shown in Table 7. The mean Haemoglobin for Liver care Churna for zero day was considered. As comparison with zero week, Haemoglobin level increase on first and second, on third week, fourth and sixth week haemoglobin level decreases slightly but in comparison with zero week it is increased. The P value is insignificant for haemoglobin shown in Table 8.

Comparative study of Haemoglobin of *Eclipta prostrata* and Liver care Churna is shown in figure 3.

Duration in week	Mean	Standard Deviation	Standard Error of Mean	Median
Initial	10.760	1.755	0.1764	10.900
First	10.901	1.729	0.1737	11.000
Second	11.043	1.763	0.1890	11.100
Third	11.207	1.777	0.2239	11.300
Fourth	10.976	1.620	0.2739	10.976
Sixth	11.131	1.561	0.4173	11.215

 Table 7: P value of HB for Eclipta prostrata

The P value is 0.6946, considered not significant.

 Table 8: P value of HB for Liver care Churna

Duration in week	Mean	Standard Deviation	Standard Error of Mean	Median
Initial	10.444	1.395	0.1402	10.4
First	10.667	1.368	0.1389	10.709
Second	10.717	1.413	0.1599	10.719
Third	10.510	1.381	0.1972	10.5
Fourth	10.646	1.299	0.2296	10.615
Sixth	10.260	1.107	0.3339	9.9

The P value is 0.7110, considered not significant.




Figure 3

Comparative study of Haemoglobin v/s week. Column graph showing value of haemoglobin for different week using *Eclipta prostrata* and Liver care Churna.

CONCLUSION

Treatment with Polyherbal formulation Liver care Churna and *Eclipta prostrata* both produces improvement in SGPT, Bilirubin, and Heamoglobin profiles in liver damage patients. The powder of *Liver care Churna* showed potent antihepatoprotactive activity and recover immediately SGPT as compared to *Eclipta prostrata*. The Liver care Churna could become helpful for liver damage possibly by reducing SGPT, Bilirubin and HB and improvement in life style of such patients.

REFERENCES

- Patel RB, Raval JD, Gandhi TP, Chakravarthy BK: Hepatoprotective effect of Indian Medicinal Plants – Part I. Indian Drugs 1998; 25(6): 224.
- 2. Rege N, Dahanukar S, Karandikar SM: Hepatoprotective effect of Piper longum against CCl₄ induced liver damage. Indian Drugs 1984; 31(2): 569.
- Khin Ma-Ma., Nyaut N, Khin Maung T: The protective effect of Eclipta alba on carbon tetra chloride induced acute liver damage Toxicol Appl Pharmacol 1978; 45: 723-728.
- 4. Reddy MB, Reddy KR, Reddy MN: A survey of medicinal plants of Chenchu tribes of Andhra Pradesh, India: Int J Crude Drug Res 1988; 26(4): 189-196.
- 5. Schmucker W, Die pflanzliche: und mineralische Materia medica im Firdaus alhikma des: Cambridge University Press: Bonn, Germany, 1969; 282-3,
- Atahara A, Wahid M, Chowdhary M, Roy J: Medicinal Plants Used In Traditional Systems Of Medicine In Bangladesh. Third Int Conf, Traditional Asian Med, Bombay, 1990; 55-65.
- Lin CC: Crude drugs used for the treatment of diabetes mellitus in Tiwan. Amer J Chinese Med 1992; 20(3/4): 269-279
- Gupta PL: Amalaki Rasayana in the treatment of chronic peptic ulcer. J Res Indian Medicine Yoga and Homoeopathy 1977; 12(1): 80-84.
- Lin CC, Chen JY, Namba T: Development of Natural Crude Drug Resources from Taiwan Iv. Pharmacognostical Studies on the Chinese Crude Drug Han-Lian-Cao. Shoyakugaku Zassi 1986; 40(4): 357-66.

www.pharmasm.com

- Vaishwanar I, Kowale CN, Jiddewar GG: Effect of two ayurvedic drugs shilajeet & eclinol on changes in liver & serum lipids produced by carbon tetrachloride. Indian J Exp Biol 1976; 14: 58-60.
- Chandra T, Sadique J: A new recipe for liver injury. Ancient Sci Life 1987; 7(2): 99-103.
- 12. Dixit SP, Achar MP: Bhringaraj in the treatment of infective hepatitis. Curr Med Pract 1979; 23(6): 237-242.
- 13. Dube CB, kumar D, Srivastava PS: A trial of bhringaraj ghanasatvavati on patients with hepatocellular jaundice. J Natl Med Ass 1982; 24(9): 265-269.
- Reitman S, Frankel SA: Colorimetric method for the determination of Serum Glutamic Oxaloacetate and Glutamic Pyruvic Transaminses. Am J Clin Pathol 1957; 28: 56-63.
- 15. Nobert T: Fundamentals of Clinical Chemistry, USA, WB Saunders Company 1970; 447-448.
- Malloy HT, Evelyn KA: The determination of Bilirubin with photoelectric colorimeter. J Biochem 1937; 481-485.
- Godkar PB, Godkar DP, Text Book of Medical Laboratory Technology. Bhalani Publishing House, Mumbai, 2nd edition, 2006.

For Correspondence:

DR. Jitendra S. Patel Asst. Professor, Department of Pharmacy, Sumandeep Vidyapeeth, Pipariya, Waghodiya road, Vadodara, 391760, Gujarat. Email: jiturx@gmail.com M- 09426362316

www.pharmasm.com